Legend Biotech Corporation | Mid-cap | Healthcare
$35.56
0.08%
| Legend Biotech Stock Comparison:
Legend Biotech vs VertexLegend Biotech vs RegeneronLegend Biotech vs BridgeBio PharmaLegend Biotech vs MadrigalLegend Biotech vs Blueprint MedicinesLegend Biotech vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 195.1M
Gross Profit 123.7M 63.42%
Operating Income -50.6M -25.97%
Net Income -100.9M -51.74%
EPS (Diluted) $-0.54

Balance Sheet Metrics

Total Assets 1.6B
Total Liabilities 597.9M
Shareholders Equity 1.0B
Debt to Equity 0.59

Cash Flow Metrics

Operating Cash Flow -71.5M
Free Cash Flow -105.8M

Revenue & Profitability Trend

Legend Biotech Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i627.2M285.1M117.0M68.8M75.0M
Cost of Goods Sold i234.6M144.2M65.4M00
Gross Profit i392.7M140.9M51.6M68.8M75.0M
Gross Margin % i62.6%49.4%44.1%100.0%100.0%
Operating Expenses
Research & Development i413.5M382.2M335.6M313.3M232.2M
Selling, General & Administrative i284.3M200.9M174.0M149.5M72.7M
Other Operating Expenses i-1.9M-2.7M-2.4M-1.7M-3.1M
Total Operating Expenses i695.9M580.4M507.3M461.1M301.8M
Operating Income i-303.2M-439.5M-455.6M-392.3M-226.8M
Operating Margin % i-48.3%-154.1%-389.4%-570.0%-302.4%
Non-Operating Items
Interest Income i61.2M54.5M8.2M971.0K2.9M
Interest Expense i21.6M21.8M10.8M900.0K195.0K
Other Non-Operating Income105.5M-113.3M12.5M-15.0M-80.2M
Pre-tax Income i-158.1M-520.1M-445.7M-407.2M-308.3M
Income Tax i18.9M-1.9M625.0K-3.6M-41.9M
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-177.0M-518.3M-446.3M-403.6M-266.4M
Net Margin % i-28.2%-181.8%-381.5%-586.4%-355.2%
Key Metrics
EBITDA i-218.1M-392.8M-438.0M-386.2M-298.3M
EPS (Basic) i$-0.96$-2.94$-2.80$-2.74$-2.56
EPS (Diluted) i$-0.96$-2.94$-2.80$-2.74$-2.56
Basic Shares Outstanding i182851072176082709159041956140851646118152617
Diluted Shares Outstanding i182851072176082709159041956140851646118152617

Income Statement Trend

Legend Biotech Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i286.7M1.3B786.0M688.9M455.7M
Short-term Investments i835.9M31.0M239.6M193.5M50.0M
Accounts Receivable i6.3M100.0M90.0K50.4M75.0M
Inventory i23.9M19.4M10.4M1.7M1.8M
Other Current Assets-----
Total Current Assets i1.3B1.5B1.1B949.8M593.9M
Non-Current Assets
Property, Plant & Equipment i94.3M72.7M46.3M31.1M0
Goodwill i174.2M155.3M68.7M16.8M2.9M
Intangible Assets i174.2M155.3M68.7M16.8M2.9M
Long-term Investments-----
Other Non-Current Assets6.1M285.0K395.0K4.1M3.5M
Total Non-Current Assets i386.2M350.8M231.8M169.6M128.1M
Total Assets i1.7B1.8B1.3B1.1B722.1M
Liabilities
Current Liabilities
Accounts Payable i37.2M19.6M31.7M7.0M4.9M
Short-term Debt i4.8M3.2M3.6M911.0K1.5M
Current Portion of Long-term Debt-----
Other Current Liabilities--67.0M87.9M-
Total Current Liabilities i277.6M216.4M297.8M229.2M115.6M
Non-Current Liabilities
Long-term Debt i345.8M325.5M281.0M122.1M1.9M
Deferred Tax Liabilities i---04.2M
Other Non-Current Liabilities-56.0K233.0K396.0K554.0K
Total Non-Current Liabilities i352.0M380.8M288.9M124.3M8.8M
Total Liabilities i629.6M597.2M586.7M353.5M124.3M
Equity
Common Stock i37.0K36.0K33.0K31.0K27.0K
Retained Earnings i-1.7B-1.5B-966.5M-520.1M-116.5M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i1.0B1.3B744.3M765.9M597.8M
Key Metrics
Total Debt i350.6M328.7M284.5M123.0M3.4M
Working Capital i1.0B1.3B801.3M720.6M478.4M

Balance Sheet Composition

Legend Biotech Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-158.1M-520.1M-445.7M-407.2M-308.3M
Depreciation & Amortization i23.4M20.5M18.4M13.9M9.9M
Stock-Based Compensation i68.9M47.7M34.3M20.2M4.8M
Working Capital Changes i36.1M-23.8M65.8M24.1M-53.5M
Operating Cash Flow i-69.8M-509.1M-318.7M-349.4M-263.5M
Investing Activities
Capital Expenditures i-14.1M-20.1M-20.9M-42.2M-26.3M
Acquisitions i-----
Investment Purchases i-2.7B-4.9B-655.0M-378.0M-72.7M
Investment Sales i1.9B5.1B614.9M230.1M98.3M
Investing Cash Flow i-850.5M95.4M-75.7M-191.8M-20.1M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i---00
Debt Repayment i-4.0M-3.8M-2.6M-1.4M-2.6M
Financing Cash Flow i-4.0M579.9M375.0M622.0M617.4M
Free Cash Flow i-158.1M-416.0M-223.6M-243.9M-253.3M
Net Change in Cash i-924.4M166.3M-19.4M80.9M333.7M

Cash Flow Trend

Legend Biotech Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -37.04
Forward P/E -53.03
Price to Book 6.33
Price to Sales 8.23
PEG Ratio -53.03

Profitability Ratios

Profit Margin -40.83%
Operating Margin -8.58%
Return on Equity -29.65%
Return on Assets -7.81%

Financial Health

Current Ratio 4.71
Debt to Equity 37.46
Beta 0.26

Per Share Data

EPS (TTM) $-1.78
Book Value per Share $5.61
Revenue per Share $4.34

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
legn6.6B-37.046.33-29.65%-40.83%37.46
Vertex 100.2B27.775.8322.77%31.86%8.89
Regeneron 62.9B14.952.0615.34%31.37%9.04
BridgeBio Pharma 9.6B-17.12-5.2836.76%98.25%-1.04
Madrigal 9.1B-18.9413.00-36.30%-54.68%17.81
Blueprint Medicines 8.4B-120.9924.43-47.71%-27.70%208.50

Financial data is updated regularly. All figures are in the company's reporting currency.